

Richmond, Virginia 23219

(Address of principal executive offices) (Zip code)

(804) 827-2524

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On May 19, 2015, AmpliPhi Biosciences Corporation issued a press release announcing its first quarter 2015 financial results.

A copy of the press release is furnished as Exhibit 99.1 to this report

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release, dated May 19, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AmpliPhi Biosciences
Corporation**

Date: May 22, 2015 By: /s/ David E. Boshier
David E. Boshier
Chief Financial
Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release, dated May 19, 2015.